Literature DB >> 18026192

A prospective study of grapefruit and grapefruit juice intake and breast cancer risk.

E H Kim, S E Hankinson, A H Eliassen, W C Willett.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 18026192      PMCID: PMC2359690          DOI: 10.1038/sj.bjc.6604105

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Sir, In a recent interesting study by Monroe , grapefruit intake was associated with an increase in breast cancer risk, and they hypothesised that this might be mediated by an effect on endogenous oestrogen levels. However, the researchers were unable to examine grapefruit juice intake. Therefore, we examined grapefruit and grapefruit juice intake and breast cancer risk in the Nurses' Health Study. Briefly, the Nurses' Health Study is a prospective cohort consisting of women aged 30–55 years in 1976 (Kim ). Medical and lifestyle information was obtained with general follow-up questionnaires every 2 years and with semi quantitative food frequency questionnaires that included intakes of grapefruit and grapefruit juice in 1984, 1986, 1990, 1994, and 1998. In both age-adjusted (not shown) and multivariate analyses adjusted for standard breast cancer risk factors, we found no overall association with either grapefruit or grapefruit juice intake and breast cancer risk among all women in the cohort, and among postmenopausal women only (Table 1). Furthermore, our results did not change once additional covariates – alcohol, saturated fat, dietary fibre, and soluble fibre – included by Monroe et al were added to our models.
Table 1

Multivariate relative risks of breast cancer incidence between 1984 and 2002 by cumulatively averaged grapefruit and grapefruit juice intake

All women 77 050 subjects (total cases=4315)
Grapefruit (per day) 0 >0–1/81/8–1/41/4 P Trend
  Cases9692576539231 
  Multivariate RR (95% CI)1.001.02 (0.94, 1.10)0.96 (0.86, 1.07)1.00 (0.86, 1.15)0.5
Grapefruit juice (small glass per day) 0 >0–1/41/41/21/2 P Trend
  Cases23351571265144 
  Multivariate RR (95% CI)1.000.96 (0.89, 1.02)1.01 (0.89, 1.15)0.95 (0.80, 1.13)0.52
      
Postmenopausal women only 73 411 subjects (total cases=3570)
Grapefruit (per day) 0 >0–1/81/8–1/41/4 P Trend
  Cases7322169469200 
  Multivariate RR (95% CI)1.001.03 (0.95, 1.12)0.97 (0.86, 1.09)0.97 (0.83, 1.14)0.34
Grapefruit juice (small glass per day) 0 >0–1/41/4–1/21/2 P Trend
  Cases18531360228129 
  Multivariate RR (95% CI)1.000.99 (0.92, 1.06)1.04 (0.90, 1.19)1.02 (0.85, 1.22)0.95

Values are adjusted for energy, age, time period, height, parity, age at first birth, weight change since age 18 years, body mass index at age 18 years, age at menopause, use of hormone replacement therapy, family history of breast cancer, benign, breast disease, age at menarche and physical activity.

Stratification by BMI did not alter the breast cancer risk with either grapefruit or grapefruit juice intake. However, stratification by hormone therapy showed a significant decrease in risk of breast cancer with greater intake of grapefruit in women who never used hormone therapy (multivariate RR comparing ¼ grapefruit or more per day to none=0.78, 95% CI, 0.59–1.04, P trend=0.03). This is contrary to the findings of Monroe et al, who observed a significant increase in risk of breast cancer with greater consumption of grapefruit in this subgroup. Furthermore, the association between grapefruit (not grapefruit juice) intake and breast cancer risk differed significantly by oestrogen and progesterone receptor status of the tumours. No association was observed in women with oestrogen and progesterone receptor positive cancers. However, in women with oestrogen and progesterone receptor negative cancers, there was a significant decrease in breast cancer risk with increased consumption of grapefruit (multivariate RR comparing ¼ grapefruit or more per day to none=0.60, 95% CI, 0.37–0.98, P trend=0.03). We also examined cross-sectionally the relationship between consumption of grapefruit and grapefruit juice and plasma levels of oestrogens among 701 postmenopausal women not using hormone replacement. No significant correlation was observed (grapefruit, grapefruit juice) for plasma oestradiol (r=0.02, −0.04), oestrone (r=0.00, −0.02), or oestrone sulphate (0.09, 0.01). Our findings do not support an adverse effect of consumption of grapefruit or grapefruit juice on risk of breast cancer or on endogenous hormone levels.
  2 in total

1.  Dietary fat and risk of postmenopausal breast cancer in a 20-year follow-up.

Authors:  Esther H J Kim; Walter C Willett; Graham A Colditz; Susan E Hankinson; Meir J Stampfer; David J Hunter; Bernard Rosner; Michelle D Holmes
Journal:  Am J Epidemiol       Date:  2006-09-12       Impact factor: 4.897

2.  Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: the Multiethnic Cohort Study.

Authors:  K R Monroe; S P Murphy; L N Kolonel; M C Pike
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

  2 in total
  3 in total

1.  Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata.

Authors:  Lauren A Wise; Rose G Radin; Julie R Palmer; Shiriki K Kumanyika; Deborah A Boggs; Lynn Rosenberg
Journal:  Am J Clin Nutr       Date:  2011-11-09       Impact factor: 7.045

2.  The effect of grapefruit intake on endogenous serum estrogen levels in postmenopausal women.

Authors:  Kristine R Monroe; Frank Z Stanczyk; Kathleen H Besinque; Malcolm C Pike
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

Review 3.  Aryl Hydrocarbon Receptor Diet and Breast Cancer Risk.

Authors:  Micah G Donovan; Ornella I Selmin; Donato F Romagnolo
Journal:  Yale J Biol Med       Date:  2018-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.